New drug combo targets aggressive blood cancer spread

NCT ID NCT06627751

Summary

This study is testing a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—to see if it can control multiple myeloma that has come back or stopped responding to other treatments and has spread to form tumors in soft tissues or organs. It will involve about 28 adults who have had at least one prior treatment. The main goal is to see how many patients' cancer shrinks or disappears in response to this new combination.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Roswell Park Cancer Institute

    RECRUITING

    Buffalo, New York, 14263, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.